Stargardt Disease
39
19
22
11
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
5.1%
2 terminated out of 39 trials
84.6%
-1.9% vs benchmark
5%
2 trials in Phase 3/4
36%
4 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (39)
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
Study of ALK-001 on the Progression of Stargardt Disease
Oral Metformin for Treatment of ABCA4 Retinopathy
Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease
Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration
Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
A Study of DC6001 Tablet in Healthy Chinese Adult Subjects
Wide Field OCTA in Ocular Diseases
Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
Feasibility and Tolerability Study of Smart Contact Lens With Healthy Subjects and Patients With Stargardt's Disease
An Observational Study in Children and Adults With Stargardt Disease
ABCA4-associated Disease in Childhood and Adolescence - a Phenotype Study
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease